Note: Displayed Aug 22, 2022; body references August 12, 2022 (historical event/reference, not necessarily publication date).
PR Team at Ubie, Inc.
Ubie, Inc., a healthcare AI startup with the mission "To develop a healthcare guide for everyone," announced that it has raised $26.2 million (1) in the 1st round of Series C funding. New investors in the round include Norinchukin Capital Co., Ltd., NVenture Capital Limited (wholly owned subsidiary of NEC Capital Solutions Limited), The Dai-ichi Life Insurance Company, Limited, and Egg FORWARD, Inc., while existing investors include SUZUKEN CO., LTD. To date, Ubie has raised $59.8 million (2).
Ubie is one of the few startups in the world with a medical data platform that has direct contact with both patients and medical institutions. Ubie offers two services that focus on the "medical questionnaire" as a gateway to healthcare, using AI as its core technology.
The "AI-powered symptom checker," provided for patients, asks around 20 questions about their symptoms to discover related diseases and provide more detailed actionable health information. Since its launch, it has been trusted by 5 million monthly users worldwide, including in Japan and the U.S.
Ubie offers "AI-powered patient intake," a service that streamlines the medical interview process for medical institutions. This service is based on a database of approximately 50,000 medical articles from around the world, created by more than 50 active physicians. The service has been introduced to more than 1,000 medical institutions worldwide and continues to improve the operational efficiency of these institutions.
Ubie will aim to bring a new medical experience to Japan and the U.S. by connecting patients, medical institutions, and pharmaceutical companies through the medical data platform it is building to solve the following medical issues;
- ensuring that patients visit the right medical institution at the right time,
- ensuring that physicians can access relevant, up-to-date knowledge from the vast amount of the latest information on diseases and rare diseases that are not their specialty, and,
- ensuring that pharmaceutical companies continue to provide patients with the appropriate information and scientific findings related to their conditions.
Series C funding will be used to fuel business growth in Japan and the U.S. to build a medical data platform that connects patients, medical institutions, and pharmaceutical companies.
Ubie Co-founder and CEO Yoshinori Abe, MD, said: "Not only in Japan, but also in other countries, the current healthcare system is suffering from various losses due to the fragmentation of information held by patients, medical institutions, and pharmaceutical companies. This fundraising aims to accelerate collaboration with pharmaceutical companies and create an unprecedented consumer-centered medical experience utilizing Ubie’s data platform. Ubie already has business with more than 20 major pharmaceutical companies in Japan and other countries, and this brings Ubie closer to realizing its mission 'To develop a healthcare guide for everyone,' both in Japan and the U.S."
Notes:
(1) $26.2 million = JPY 3.5 billion (as of August 12, 2022)
(2) $59.8 million = JPY 7.98 billion (same as above)
About Ubie's AI Symptom Checker:
U.S. Version: https://ubiehealth.com/
Japanese Version: https://ubie.app
Ubie's service enables users to easily access healthcare information and find appropriate healthcare providers. Available in both Japanese and English, it supports users in identifying symptoms and connecting with the right healthcare providers.
About Ubie, Inc.:
Ubie, Inc., established in 2017, is at the forefront of the digital health revolution. As an innovative startup, Ubie harnesses the power of artificial intelligence to seamlessly navigate individuals towards the appropriate healthcare services. Our mission is rooted in the belief that everyone, regardless of location or circumstance, deserves access to comprehensive healthcare. We are committed to transforming this vision into reality by creating a more accessible and user-friendly healthcare experience. Our global presence is anchored by our headquarters in Tokyo, Japan, situated at the heart of Nihonbashi, and our U.S. headquarters in the bustling hub of New York City. These strategic locations enable us to cultivate and expand our impact on the healthcare industry worldwide.
U.S. Headquarters:
1460 Broadway, New York, NY 10036
Japan Headquarters:
6th Floor, Nihonbashi-Horidomecho 2-chome Bldg., 2-4-3, Horidomecho, Nihonbashi, Chuo-ku, Tokyo, 103-0012
Inception:
May 2017 - Japan Operations
October 2022 - U.S. Operations
Leadership:
Co-founders, Kota Kubo and Dr. Yoshinori Abe, spearhead our ambitious journey with a shared dedication to enhancing healthcare accessibility through innovative solutions.
Discover more about our vision and endeavors at: https://ubiehealth.com/company
Contact:
Ryosei Hatakeyama
Ubie Inc.
1460 Broadway, New York, NY 10036
Email: pr@ubiehealth.com
Note to Editors: For more details or to arrange an interview with CEO Kota Kubo, please reach out to Ryosei Hatakeyama at the contact information above.